The private owners who purchased BioMet Inc. for $11 billion are considering selling the company after it lost $450 million in 2012. BioMet has recently come under fire for its M2A Magnum hip replacements, which many patients allege are failing and leading to complications.
There is some speculation that BioMet may merge with another device company that has had similar metal-on-metal hip replacement problems. BioMet could face thousands of M2A Magnum lawsuits alleging that the device caused severe side effects, including tissue damage and toxic levels of metal in the blood stream.
A 2011 study conducted in Australia found that 7.2% of patients who received an M2A Magnum hip replacement required revision surgery to remove the device. Metal-on-metal hip replacement lawsuits have been filed against several manufacturers after studies revealed the metal hip implants were more likely to lead to problems and require removal.